Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYCOVID: hydroxychloroquine versus placebo in high-risk COVID-19 patients
2020-001271-33Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire d'Angers
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine with Placebo (2 arms). Primary endpoint: Death from any cause or invasive intubation and mechanical ventilation by day 14. Started Mar 2020; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001271-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001271-33.